Sumitomo Pharma Co Ltd 2011 AR2
The report outlines Dainippon Sumitomo Pharma's financial and operational performance for the fiscal year ended March 31, 2011, highlighting its progress toward global growth. A key milestone was the U.S. launch of its global strategic atypical antipsychotic agent, LATUDA, and a co-development alliance in Europe with Takeda Pharmaceutical. The company also advanced its R&D pipeline in focus areas like central nervous system disorders and oncology. Additionally, the report details the company's corporate social responsibility initiatives, including disaster relief efforts following the Great East Japan Earthquake and its environmental performance under the Mid-term Environmental Plan.
Company: Sumitomo Pharma Co Ltd
Sector: Health Care
Country: Japan
Year: 2011
Type: AR2
Pages: 78
Sumitomo Pharma Co Ltd
Annual Report
The report outlines Dainippon Sumitomo Pharma's financial and operational performance for the fiscal year ended March 31, 2011, highlighting its progress toward global growth. A key milestone was the U.S. launch of its global strategic atypical antipsychotic agent, LATUDA, and a co-development alliance in Europe with Takeda Pharmaceutical. The company also advanced its R&D pipeline in focus areas like central nervous system disorders and oncology. Additionally, the report details the company's corporate social responsibility initiatives, including disaster relief efforts following the Great East Japan Earthquake and its environmental performance under the Mid-term Environmental Plan.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2011
Reporting Period
Apr 1, 2010 - Mar 31, 2011
Fiscal Year
2011
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Total Waste
Employees